During tumor progression, endothelial cells undergo an angiogenic switch, which has long been considered to be dictated by angiogenic activators, such as VEGFs, IL-8, tumor necrosis factor α (TNF-α), and hypoxia-inducible factors (HIFs) [26] and other signaling pathways (e.g., Notch). The gene discussed is TNF; the disease is neoplasm.